StudyReasons for exclusion
Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol- lowering treatment: prospective meta- analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267–1278.Meta analysis
Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383–1389.21% of participants with angina
Wilt VM, Gums JG. ‘Isolated’ low high- density lipoprotein cholesterol. Ann Pharmacother. 1997; 31(1):89–97.review
Perrone-Filardi P, Corrado L, Brevetti G et al. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease. J Clin Hypertens. 2009; 11(5):260–265.Outcomes outside remit
Murphy SA. Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). ACC Cardiosource Review Journal. 2007; 16(12):77.abstract
Baller D, Notohamiprodjo G, Gleichmann U et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation. 1999; 99(22):2871–2875.N=23
Houghton JL, Pearson TA, Reed RG et al. Cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary arteriograms.[see comment]. Chest. 2000; 118(3):756–760.N=6
Deedwania PC, Hunninghake DB, Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol. 2004; 93(11):18C–26c.Patients with metabolic syndrome
Barzilay JI, Jones CL, Davis BR et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001; 24(4):654–658.Methodology paper
Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.[see comment]. Lancet. 2007; 369(9571):1431–1439.No stable angina patients

From: Appendix E, Included – Excluded Studies and Clinical Evidence Tables

Cover of Stable Angina
Stable Angina: Methods, Evidence & Guidance [Internet].
NICE Clinical Guidelines, No. 126.
National Clinical Guidelines Centre (UK).
Copyright © 2011, National Clinical Guidelines Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of the National Clinical Guidelines Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.